Do analysts recommend NNVC or ERNA?

Ernexa Therapeutics has a consensus price target of $30.00, suggesting a potential upside of 378.47%. Given Ernexa Therapeutics' higher probable upside, analysts plainly believe Ernexa Therapeutics is more favorable than NanoViricides. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NanoViricides 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Ernexa Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is NNVC or ERNA more profitable?

NanoViricides' return on equity of -87.90% beat Ernexa Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets NanoViricides N/A -87.90% -78.69% Ernexa Therapeutics N/A -263.74% -151.16%

Does the media prefer NNVC or ERNA?

In the previous week, Ernexa Therapeutics had 2 more articles in the media than NanoViricides. MarketBeat recorded 3 mentions for Ernexa Therapeutics and 1 mentions for NanoViricides. Ernexa Therapeutics' average media sentiment score of 0.25 beat NanoViricides' score of 0.25 indicating that Ernexa Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NanoViricides 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ernexa Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate VIRI or ERNA?

Ernexa Therapeutics has a consensus price target of $30.00, suggesting a potential upside of 378.47%. Given Ernexa Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Ernexa Therapeutics is more favorable than Virios Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Virios Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Ernexa Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is VIRI or ERNA more profitable?

Virios Therapeutics' return on equity of -130.33% beat Ernexa Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Virios Therapeutics N/A -130.33% -115.00% Ernexa Therapeutics N/A -263.74% -151.16%

Does the media prefer VIRI or ERNA?

In the previous week, Ernexa Therapeutics had 2 more articles in the media than Virios Therapeutics. MarketBeat recorded 3 mentions for Ernexa Therapeutics and 1 mentions for Virios Therapeutics. Ernexa Therapeutics' average media sentiment score of 0.25 beat Virios Therapeutics' score of 0.00 indicating that Ernexa Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Virios Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ernexa Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is ERNA or LSTA more profitable?

Lisata Therapeutics' return on equity of -103.54% beat Ernexa Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Ernexa Therapeutics N/A -263.74% -151.16% Lisata Therapeutics N/A -103.54% -83.08%

Is ERNA or ATNM more profitable?

Actinium Pharmaceuticals' return on equity of -100.85% beat Ernexa Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Ernexa Therapeutics N/A -263.74% -151.16% Actinium Pharmaceuticals N/A -100.85% -47.89%

Does the media favor ERNA or KYNB?

In the previous week, Ernexa Therapeutics had 2 more articles in the media than Kyntra Bio. MarketBeat recorded 3 mentions for Ernexa Therapeutics and 1 mentions for Kyntra Bio. Ernexa Therapeutics' average media sentiment score of 0.25 beat Kyntra Bio's score of 0.00 indicating that Ernexa Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ernexa Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Kyntra Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Ernexa Therapeutics (ERNA) Competitors

$6.27 0.00 (0.00%)

Closing price 07/2/2026 03:59 PM Eastern

Extended Trading

$6.20 -0.06 (-1.04%)

As of 07/2/2026 07:59 PM Eastern

Compare

ERNA vs. NNVC, VIRI, LSTA, ATNM, and KYNB

Should you buy Ernexa Therapeutics stock or one of its competitors? MarketBeat compares Ernexa Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Ernexa Therapeutics include NanoViricides (NNVC), Virios Therapeutics (VIRI), Lisata Therapeutics (LSTA), Actinium Pharmaceuticals (ATNM), and Kyntra Bio (KYNB). These companies are all part of the "pharmaceutical products" industry.

How does Ernexa Therapeutics compare to NanoViricides?

NanoViricides (NYSE:NNVC) and Ernexa Therapeutics (NASDAQ:ERNA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

NanoViricides has higher earnings, but lower revenue than Ernexa Therapeutics. NanoViricides is trading at a lower price-to-earnings ratio than Ernexa Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NanoViricides	N/A	N/A	-$8.29M	-$0.43	N/A
Ernexa Therapeutics	$580K	12.65	-$14.08M	-$26.20	N/A

NanoViricides has a beta of 1.67, suggesting that its stock price is 67% more volatile than the broader market. Comparatively, Ernexa Therapeutics has a beta of 2.5, suggesting that its stock price is 150% more volatile than the broader market.

NanoViricides' return on equity of -87.90% beat Ernexa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NanoViricides	N/A	-87.90%	-78.69%
Ernexa Therapeutics	N/A	-263.74%	-151.16%

10.3% of NanoViricides shares are owned by institutional investors. Comparatively, 70.6% of Ernexa Therapeutics shares are owned by institutional investors. 3.6% of NanoViricides shares are owned by insiders. Comparatively, 0.5% of Ernexa Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Ernexa Therapeutics had 2 more articles in the media than NanoViricides. MarketBeat recorded 3 mentions for Ernexa Therapeutics and 1 mentions for NanoViricides. Ernexa Therapeutics' average media sentiment score of 0.25 beat NanoViricides' score of 0.25 indicating that Ernexa Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NanoViricides	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ernexa Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Ernexa Therapeutics has a consensus price target of $30.00, suggesting a potential upside of 378.47%. Given Ernexa Therapeutics' higher probable upside, analysts plainly believe Ernexa Therapeutics is more favorable than NanoViricides.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NanoViricides	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Ernexa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Ernexa Therapeutics beats NanoViricides on 7 of the 13 factors compared between the two stocks.

How does Ernexa Therapeutics compare to Virios Therapeutics?

Virios Therapeutics (NASDAQ:VIRI) and Ernexa Therapeutics (NASDAQ:ERNA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

Virios Therapeutics' return on equity of -130.33% beat Ernexa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Virios Therapeutics	N/A	-130.33%	-115.00%
Ernexa Therapeutics	N/A	-263.74%	-151.16%

Ernexa Therapeutics has a consensus price target of $30.00, suggesting a potential upside of 378.47%. Given Ernexa Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Ernexa Therapeutics is more favorable than Virios Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Virios Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Ernexa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Ernexa Therapeutics had 2 more articles in the media than Virios Therapeutics. MarketBeat recorded 3 mentions for Ernexa Therapeutics and 1 mentions for Virios Therapeutics. Ernexa Therapeutics' average media sentiment score of 0.25 beat Virios Therapeutics' score of 0.00 indicating that Ernexa Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Virios Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ernexa Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Virios Therapeutics has higher earnings, but lower revenue than Ernexa Therapeutics. Virios Therapeutics is trading at a lower price-to-earnings ratio than Ernexa Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Virios Therapeutics	N/A	N/A	-$5.30M	-$0.27	N/A
Ernexa Therapeutics	$580K	12.65	-$14.08M	-$26.20	N/A

9.1% of Virios Therapeutics shares are held by institutional investors. Comparatively, 70.6% of Ernexa Therapeutics shares are held by institutional investors. 12.2% of Virios Therapeutics shares are held by company insiders. Comparatively, 0.5% of Ernexa Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Virios Therapeutics has a beta of 1.58, meaning that its stock price is 58% more volatile than the broader market. Comparatively, Ernexa Therapeutics has a beta of 2.5, meaning that its stock price is 150% more volatile than the broader market.

Summary

Ernexa Therapeutics beats Virios Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Ernexa Therapeutics compare to Lisata Therapeutics?

Ernexa Therapeutics (NASDAQ:ERNA) and Lisata Therapeutics (NASDAQ:LSTA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, valuation, risk, profitability and institutional ownership.

70.6% of Ernexa Therapeutics shares are held by institutional investors. Comparatively, 8.9% of Lisata Therapeutics shares are held by institutional investors. 0.5% of Ernexa Therapeutics shares are held by insiders. Comparatively, 9.6% of Lisata Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Lisata Therapeutics' return on equity of -103.54% beat Ernexa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ernexa Therapeutics	N/A	-263.74%	-151.16%
Lisata Therapeutics	N/A	-103.54%	-83.08%

Ernexa Therapeutics has higher revenue and earnings than Lisata Therapeutics. Lisata Therapeutics is trading at a lower price-to-earnings ratio than Ernexa Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ernexa Therapeutics	$580K	12.65	-$14.08M	-$26.20	N/A
Lisata Therapeutics	$170K	178.45	-$16.59M	-$1.86	N/A

In the previous week, Ernexa Therapeutics had 3 more articles in the media than Lisata Therapeutics. MarketBeat recorded 3 mentions for Ernexa Therapeutics and 0 mentions for Lisata Therapeutics. Ernexa Therapeutics' average media sentiment score of 0.25 beat Lisata Therapeutics' score of 0.00 indicating that Ernexa Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Ernexa Therapeutics	Neutral
Lisata Therapeutics	Neutral

Ernexa Therapeutics currently has a consensus price target of $30.00, indicating a potential upside of 378.47%. Lisata Therapeutics has a consensus price target of $15.00, indicating a potential upside of 350.45%. Given Ernexa Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Ernexa Therapeutics is more favorable than Lisata Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ernexa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Lisata Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Ernexa Therapeutics has a beta of 2.5, meaning that its stock price is 150% more volatile than the broader market. Comparatively, Lisata Therapeutics has a beta of 0.79, meaning that its stock price is 21% less volatile than the broader market.

Summary

Ernexa Therapeutics beats Lisata Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Ernexa Therapeutics compare to Actinium Pharmaceuticals?

Ernexa Therapeutics (NASDAQ:ERNA) and Actinium Pharmaceuticals (NYSE:ATNM) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, dividends, analyst recommendations, risk, profitability, media sentiment and institutional ownership.

70.6% of Ernexa Therapeutics shares are owned by institutional investors. Comparatively, 27.5% of Actinium Pharmaceuticals shares are owned by institutional investors. 0.5% of Ernexa Therapeutics shares are owned by company insiders. Comparatively, 0.6% of Actinium Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Ernexa Therapeutics has higher revenue and earnings than Actinium Pharmaceuticals. Actinium Pharmaceuticals is trading at a lower price-to-earnings ratio than Ernexa Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ernexa Therapeutics	$580K	12.65	-$14.08M	-$26.20	N/A
Actinium Pharmaceuticals	$90K	341.99	-$48.82M	-$0.75	N/A

Actinium Pharmaceuticals' return on equity of -100.85% beat Ernexa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ernexa Therapeutics	N/A	-263.74%	-151.16%
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%

Ernexa Therapeutics has a beta of 2.5, meaning that its share price is 150% more volatile than the broader market. Comparatively, Actinium Pharmaceuticals has a beta of -0.02, meaning that its share price is 102% less volatile than the broader market.

Ernexa Therapeutics currently has a consensus target price of $30.00, indicating a potential upside of 378.47%. Actinium Pharmaceuticals has a consensus target price of $5.00, indicating a potential upside of 409.68%. Given Actinium Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Actinium Pharmaceuticals is more favorable than Ernexa Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ernexa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Actinium Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, Ernexa Therapeutics had 3 more articles in the media than Actinium Pharmaceuticals. MarketBeat recorded 3 mentions for Ernexa Therapeutics and 0 mentions for Actinium Pharmaceuticals. Ernexa Therapeutics' average media sentiment score of 0.25 beat Actinium Pharmaceuticals' score of 0.00 indicating that Ernexa Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Ernexa Therapeutics	Neutral
Actinium Pharmaceuticals	Neutral

Summary

Ernexa Therapeutics and Actinium Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.

How does Ernexa Therapeutics compare to Kyntra Bio?

Ernexa Therapeutics (NASDAQ:ERNA) and Kyntra Bio (NASDAQ:KYNB) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, valuation, institutional ownership, dividends, risk and analyst recommendations.

Ernexa Therapeutics currently has a consensus target price of $30.00, suggesting a potential upside of 378.47%. Kyntra Bio has a consensus target price of $30.00, suggesting a potential upside of 293.18%. Given Ernexa Therapeutics' higher probable upside, analysts plainly believe Ernexa Therapeutics is more favorable than Kyntra Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ernexa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Kyntra Bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Ernexa Therapeutics has a beta of 2.5, meaning that its stock price is 150% more volatile than the broader market. Comparatively, Kyntra Bio has a beta of 0.96, meaning that its stock price is 4% less volatile than the broader market.

In the previous week, Ernexa Therapeutics had 2 more articles in the media than Kyntra Bio. MarketBeat recorded 3 mentions for Ernexa Therapeutics and 1 mentions for Kyntra Bio. Ernexa Therapeutics' average media sentiment score of 0.25 beat Kyntra Bio's score of 0.00 indicating that Ernexa Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ernexa Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kyntra Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Kyntra Bio has higher revenue and earnings than Ernexa Therapeutics. Ernexa Therapeutics is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ernexa Therapeutics	$580K	12.65	-$14.08M	-$26.20	N/A
Kyntra Bio	$6.44M	4.80	$183.45M	$40.46	0.19

70.6% of Ernexa Therapeutics shares are held by institutional investors. Comparatively, 72.7% of Kyntra Bio shares are held by institutional investors. 0.5% of Ernexa Therapeutics shares are held by company insiders. Comparatively, 4.2% of Kyntra Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Kyntra Bio has a net margin of 2,199.13% compared to Ernexa Therapeutics' net margin of 0.00%. Kyntra Bio's return on equity of 0.00% beat Ernexa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ernexa Therapeutics	N/A	-263.74%	-151.16%
Kyntra Bio	2,199.13%	N/A	-36.71%

Summary

Kyntra Bio beats Ernexa Therapeutics on 11 of the 16 factors compared between the two stocks.

Get Ernexa Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ERNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ERNA vs. The Competition

Export

Metric	Ernexa Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$7.31M	$3.10B	$7.16B	$12.48B
Dividend Yield	N/A	2.05%	2.66%	6.52%
P/E Ratio	-0.24	20.06	28.02	24.70
Price / Sales	12.65	360.33	540.37	99.49
Price / Cash	N/A	57.49	49.26	57.09
Price / Book	0.82	4.32	10.96	6.46
Net Income	-$14.08M	$64.45M	$3.57B	$337.01M
7 Day Performance	-10.04%	2.97%	2.12%	1.69%
1 Month Performance	-20.53%	6.83%	5.25%	3.81%
1 Year Performance	-87.14%	29.07%	33.29%	23.90%

Ernexa Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ERNA Ernexa Therapeutics	3.746 of 5 stars	$6.27 flat	$30.00 +378.5%	-87.1%	$7.31M	$580K	N/A	10	News Coverage Gap Down
NNVC NanoViricides	0.3813 of 5 stars	$1.35 -2.2%	N/A	-5.0%	$31.03M	N/A	N/A	20
VIRI Virios Therapeutics	N/A	$1.61 -9.6%	N/A	-69.0%	$31.01M	N/A	N/A	5	Gap Up
LSTA Lisata Therapeutics	2.2797 of 5 stars	$3.36 -1.2%	$15.00 +346.4%	+26.1%	$30.96M	$170K	N/A	30
ATNM Actinium Pharmaceuticals	2.0098 of 5 stars	$0.98 0.0%	$5.00 +410.3%	-31.9%	$30.74M	$90K	N/A	30

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ERNA) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ernexa Therapeutics (ERNA) Competitors

ERNA vs. NNVC, VIRI, LSTA, ATNM, and KYNB

How does Ernexa Therapeutics compare to NanoViricides?

Summary

How does Ernexa Therapeutics compare to Virios Therapeutics?

Summary

How does Ernexa Therapeutics compare to Lisata Therapeutics?

Summary

How does Ernexa Therapeutics compare to Actinium Pharmaceuticals?

Summary

How does Ernexa Therapeutics compare to Kyntra Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ERNA vs. The Competition

Ernexa Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ernexa Therapeutics (ERNA) Competitors

ERNA vs. NNVC, VIRI, LSTA, ATNM, and KYNB

How does Ernexa Therapeutics compare to NanoViricides?

Which has stronger earnings & valuation, NNVC or ERNA?

Which has more volatility and risk, NNVC or ERNA?

Is NNVC or ERNA more profitable?

Do institutionals & insiders have more ownership in NNVC or ERNA?

Does the media prefer NNVC or ERNA?

Do analysts recommend NNVC or ERNA?

Summary

How does Ernexa Therapeutics compare to Virios Therapeutics?

Is VIRI or ERNA more profitable?

Do analysts rate VIRI or ERNA?

Does the media prefer VIRI or ERNA?

Which has stronger valuation & earnings, VIRI or ERNA?

Do institutionals and insiders hold more shares of VIRI or ERNA?

Which has more volatility and risk, VIRI or ERNA?

Summary

How does Ernexa Therapeutics compare to Lisata Therapeutics?

Do insiders & institutionals hold more shares of ERNA or LSTA?

Is ERNA or LSTA more profitable?

Which has stronger earnings and valuation, ERNA or LSTA?

Does the media favor ERNA or LSTA?

Do analysts prefer ERNA or LSTA?

Which has more risk & volatility, ERNA or LSTA?

Summary

How does Ernexa Therapeutics compare to Actinium Pharmaceuticals?

Do insiders and institutionals hold more shares of ERNA or ATNM?

Which has better valuation and earnings, ERNA or ATNM?

Is ERNA or ATNM more profitable?

Which has more volatility & risk, ERNA or ATNM?

Do analysts prefer ERNA or ATNM?

Does the media favor ERNA or ATNM?

Summary

How does Ernexa Therapeutics compare to Kyntra Bio?

Do analysts prefer ERNA or KYNB?

Which has more volatility and risk, ERNA or KYNB?

Does the media favor ERNA or KYNB?

Which has higher valuation and earnings, ERNA or KYNB?

Do insiders & institutionals have more ownership in ERNA or KYNB?

Is ERNA or KYNB more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ERNA vs. The Competition

Ernexa Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools